Table 3

Symptoms, examination and medication at presentation for patients in modified WHO II–IV

All patients (n=152)Presenting prepartum (n=122)Presenting postpartum (n=30)p Value
Symptoms and severity of disease, n (%)
 Palpitations64 (42)54 (44)10 (33)0.27
 Presyncope/syncope1 (0)1 (0)0 (0)0.58
 Chest pain5 (3)4 (3)1 (3)1.00
NYHA FC
 I/II120 (79)108 (89)12 (40)<0.001
 III32 (21)14 (11)18 (60)<0.001
Modified WHO group
 II-III98 (64)98 (80)0 (0)<0.001
 IV54 (36)24 (20)30 (100)<0.001
Vital signs
 Heart rate in bpm90±1987±17103±19<0.0001
 SBP in mm Hg119±16121±15111±170.001
 DBP in mm Hg74±1174±1274±110.79
Physical examination, n (%)
 Jugular venous pressure >542 (28)20 (16)22 (73)<0.001
 Crepitations40 (26)21 (18)19 (63)<0.001
 Oedema29 (19)15 (12)14 (47)<0.001
 Systolic heart murmur86 (57)60 (49)26 (87)<0.001
 Diastolic heart murmur7 (5)7 (6)0 (0)0.17
Laboratory tests
 Haemoglobin (g/dL)11.5±1.911.5±1.711.4±2.40.11
 HIV positive36 (24)26 (21)10 (36)0.17
 NTProBNP* (median, range)629.3 (130–6400)459.6 (130–4885)1589.9 (130–6400)<0.0001
 Log NTProBNP6.38±1.046.15+0.987.16+0.89<0.0001
ECG, n (%)
 Sinus rhythm127 (83)103 (84)24 (86)0.79
 Sinus tachycardia13 (9)8 (7)5 (17)0.09
 Atrial fibrillation1 (1)1 (3)0 (0)0.34
Echocardiogram
 LVEDD (mm)50.6±8.548.6±7.758.7±6.5<0.0001
 LVESD (mm)36.9±10.133.4±7.650.4±6.9<0.0001
 EF (%) (n=62)51.1±13.054.5±12.444.7±11.80.003
Medications at baseline visit, n (%)
 ACE inhibitor505
 Aldosterone antagonist101
 Aspirin330
 Beta blocker1091
 Bromocriptine505
 Calcium channel blocker761
 Digoxin110
 Hydralazine110
 Nitrate000
 Furosemide341816
 Thiazide16151
 Warfarin990
  • *NTproBNP measurements were only performed in 110 patients.

  • DBP, diastolic blood pressure; LVESD, left ventricle in end-systolic diameter; LVEDD, left ventricle in end-diastolic diameter; NYHA FC, New York Heart Association Functional Class; SBP, systolic blood pressure; ACE inhibitor, angiotensin-converting-enzyme inhibitor.